GlassScriptPhysician profile
Kemar Earl Green
NPI 1184013633
$1,048.65
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2022: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $500.80 | 2019 | |
| Amgen INC. | $120.80 | 2019 | |
| Biogen, INC. | $113.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $110.42 | 2019 | |
| Boston Scientific Corporation | $77.90 | 2019 | |
| Genzyme Corporation | $62.16 | 2022 | |
| Horizon Therapeutics Plc | $49.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kemar Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.